From award-winning skincare products to first aid, hydration, sunscreen, and bug bite relief, FSAs and HSAs help families and individuals make the most of summer fun...
New executives bring deep expertise to elevate quality and accelerate innovation across global operations
SAN DIEGO, July 7, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the...
München, Deutschland, 04. Juli 2025 – Das Komitee des Strüngmann Award gab heute bekannt, dass Dr. Dragan Grabulovski, Dr. Philipp Spycher und Dr. Isabella Attinger-Toller, die Gründer von Araris Biotech, als die diesjährigen Preisträger ausgezeichnet wurden. Der Award verfolgt das Ziel, herausragende unternehmerische und wissenschaftliche Leistungen sowie bahnbrechende Ideen in der Life-Science-Branche zu fördern. Das Gründerteam von Araris Biotech überzeugte nicht nur durch die Entwicklung einer neuartigen Technologie im Bereich der Antikörper-Wirkstoff-Konjugate, sondern auch durch deren erfolgreiche Validierung in Form von Partnerschaften und einem präklinischen Exit. Diese neue Medikamentenklasse hat das Potenzial, maßgeblich zur Weiterentwicklung zielgerichteter Krebstherapien beizutragen und somit einen Mehrwert für Menschen mit Krebserkrankungen weltweit zu erreichen.
Munich, Germany, July 04, 2025 – The Strüngmann Award selection committee today announced that Dragan Grabulovski, Ph.D., Philipp Spycher, Ph.D., and Isabella Attinger-Toller, Ph.D., the founders of Araris Biotech, have been honored as this year’s winners. The award aims to support outstanding entrepreneurial and scientific achievements, as well as ground-breaking ideas in the life sciences industry. Araris Biotech’s founding team distinguished itself not only by developing of a novel technology in the antibody-drug conjugates (ADCs) field, but also by successfully validating this innovation through partnerships and a preclinical exit. This new drug class has the potential to significantly advance the development of targeted cancer therapies, thereby delivering added value for people living with cancer worldwide.
The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific...
The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific...
The NOX-targeted therapy market is expected to expand significantly over the upcoming years as more therapies move into late-stage development and gain regulatory approval....
The NOX-targeted therapy market is expected to expand significantly over the upcoming years as more therapies move into late-stage development and gain regulatory approval....
"Metastatic Cancer: A Significant Therapeutic Challenge as Pharmaceutical Companies Leverage Digital Platforms and Data to Enhance Engagement with Patients, Providers, and Regulators in the...
VALLEY FORGE, Pa., June 30, 2025 /PRNewswire/ -- PJM Interconnection has appointed Deena O'Brien as senior director of corporate communications with responsibility for external...
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape...
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape...
SAN DIEGO and CHICAGO, June 30, 2025 /PRNewswire/ -- HealthpointCapital, the leading private equity firm focused exclusively on musculoskeletal healthcare, today announced the acquisition...
The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...